Skip to content
Clinical Trials – home
IrelandBack to Ireland

Clinical trials in Mullingar

7 clinical trials in Mullingar, Ireland. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mullingar at a glance
7
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

7 trials in Mullingar

Open in trial search
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited
Countries:IrelandIreland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited
Countries:IrelandIreland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Generate Biomedicines Inc.

Crohn's disease

Recruiting
Investigational
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Kan-101
  • Sponsor:Kanyos Bio Inc.
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Other cities in Ireland

The busiest research cities in the country

All 16 cities in Ireland

Clinical research in Mullingar

What the registry says about research in the country

01 Gastrointestinal Disorders

Innovative research focusing on celiac disease treatment, evaluating a novel therapeutic agent KAN-101 for its effectiveness in protecting against gluten-induced intestinal changes.

  • Celiac Disease Management
  • Intestinal Mucosa Protection
  • Gluten Challenge Response

The trials aim to measure changes in intestinal tissue structure and assess therapeutic tolerance.

02 Inflammatory Bowel Disease

Comprehensive studies on ulcerative colitis examining the novel compound obefazimod, with both short-term and long-term evaluation protocols for efficacy and safety.

  • Endoscopic Improvement
  • Symptomatic Remission
  • Long-term Safety Assessment

Research focuses on moderate to severe cases with extended follow-up periods.

03 Advanced Digestive Disease Research

Groundbreaking research into Crohn's Disease treatment, investigating targeted therapies for adult patients with moderate to severe symptoms.

  • Therapeutic Efficacy
  • Safety Profiling
  • Mechanistic Assessment

The studies aim to advance personalized treatment approaches for inflammatory bowel conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).